Angular Furoquinolinones, Psoralen Analogs:  Novel Antiproliferative Agents for Skin Diseases. Synthesis, Biological Activity, Mechanism of Action, and Computer-Aided Studies

1996 ◽  
Vol 39 (6) ◽  
pp. 1293-1302 ◽  
Author(s):  
Paolo Rodighiero ◽  
Adriano Guiotto ◽  
Adriana Chilin ◽  
Franco Bordin ◽  
Francarosa Baccichetti ◽  
...  
Keyword(s):  
Biological Activity ◽  
Mechanism Of Action ◽  
Skin Diseases ◽  
Antiproliferative Agents ◽  
Computer Aided ◽  
Activity Mechanism

Review of the biological activity of maslinic acid1

2021 ◽  
Vol 22 ◽  
Author(s):  
Zhang Jing ◽  
Wang Rui ◽  
Li Ruihua ◽  
Yu Hao ◽  
Fang Hengtong
Keyword(s):  
Biological Activity ◽  
Cardiovascular Diseases ◽  
Animal Models ◽  
Mechanism Of Action ◽  
Maslinic Acid ◽  
Animal Models Of Disease ◽  
Positive Effects ◽  
Cancer Inflammation ◽  
Models Of Disease

: Since the discovery of (2α,3β)-2,3-dihydroxyolean-12-en-28-oic acid, also known as maslinic acid, many studies have examined its biological activity, which has been shown to promote health and resist various diseases. This article focuses on previous research on maslinic acid and mainly reviews its reported effects on cardiovascular diseases, neuroprotection, diabetes, cancer, inflammation, and pathogens. Maslinic acid exerts positive effects on both cell and animal models of disease. Although its mechanism of action has not yet been completely elucidated, maslinic acid is feasible as a nutritional additive and has the potential to be developed as a drug.

scholarly journals Differential Binding and Neutralization of Activins A and B by Follistatin and Follistatin Like-3 (FSTL-3/FSRP/FLRG)

Endocrinology ◽  
2003 ◽  
Vol 144 (5) ◽  
pp. 1671-1674 ◽  
Author(s):  
Alan Schneyer ◽  
Amy Schoen ◽  
Alicia Quigg ◽  
Yisrael Sidis
Keyword(s):  
Biological Activity ◽  
Mechanism Of Action ◽  
Relative Activity ◽  
Activin A ◽  
Primary Mechanism ◽  
Wide Availability ◽  
Reporter Assays ◽  
Differential Binding ◽  
Tgfβ Superfamily

Modulation of activin and other TGFβ superfamily signaling is the primary mechanism of action for both follistatin (FS) and FS-like 3 (FSTL-3). However, most studies of these ligands use activin A due to its wide availability. We have now tested the ability of FS288 and FSTL-3 to bind and neutralize activin B relative to activin A. Activin B bound to both FS and FSTL-3 at a potency approximately 10-fold lower than that of activin A. Moreover, whereas both activins had similar biological activity in 293 cell reporter assays, FS and FSTL-3 were approximately 3-fold more effective in neutralizing activin A relative to activin B. These results suggest that neutralization of activins A and B by FS and FSTL-3 are not identical, so that the relative activity of each activin in tissues where both are produced, such as in the ovary, could be quite different. In addition, biological systems that use primarily activin B, but which have been examined in vitro using activin A, may need to be reevaluated to determine the actual physiologic roles of FS or FSTL-3.

Calcineurin Inhibitors: A Novel Approach to Canine Atopic Dermatitis

2005 ◽  
Vol 41 (2) ◽  
pp. 92-97 ◽  
Author(s):  
Rosanna Marsella
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Effects ◽  
Mechanism Of Action ◽  
Broad Spectrum ◽  
Skin Diseases ◽  
Calcineurin Inhibitors ◽  
Relevant Information ◽  
Novel Approach ◽  
Allergic Skin ◽  
Traditional Therapies

The introduction of calcineurin inhibitors represents a major addition to the armamentarium of drugs available to veterinary clinicians for the management of allergic skin diseases. Both cyclosporine and tacrolimus have been proven to be well tolerated and effective for the treatment of atopic dermatitis in dogs. Although broad spectrum in their mechanism of action, they lack the major adverse effects of glucocorticoids and provide an appealing alternative to traditional therapies. The purposes of this article are to review clinically relevant information regarding these agents and to provide tips for maximizing the benefit obtained from these therapies.

scholarly journals CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy

2016 ◽  
Vol 7 (3) ◽  
pp. 196-210 ◽  
Author(s):  
Huiying Sun ◽  
Sanjay N. Mediwala ◽  
Adam T. Szafran ◽  
Michael A. Mancini ◽  
Marco Marcelli
Keyword(s):  
Androgen Receptor ◽  
Mechanism Of Action ◽  
Full Length ◽  
In Vivo Efficacy ◽  
Activity Mechanism

Synthesis, Biological Activity, and Mechanism of Action of Mono-Substituted 5-Halouracil Salts

2014 ◽  
Vol 48 (4) ◽  
pp. 235-237 ◽  
Author(s):  
M. Kh. Salimgareeva ◽  
E. I. Farafontova ◽  
G. S. Abdrakhimova ◽  
S. P. Ivanov ◽  
Yu. V. Vakhitova
Keyword(s):  
Biological Activity ◽  
Mechanism Of Action
Sign in / Sign up

Export Citation Format

Share Document